2 days ago
Sarawak steps into global biomedical arena with launch of research society
Dr Samuel Ting Chuo Yew
KUCHING (June 14): The Sarawak Society for Cell and Gene Therapy Research (SSCTR) has been officially launched, marking a significant step forward in positioning Sarawak as a contributor to the global biomedical innovation landscape.
Founded by Dr Samuel Ting Chuo Yew, a leading figure in pharmaceutical science and health policy, the SSCTR aims to promote awareness, foster collaboration, and support policy development in the rapidly evolving field of cell and gene therapy (CGT).
'Cell and gene therapy is revolutionizing modern medicine, from offering cures for previously untreatable genetic disorders to enabling personalized regenerative therapies,' said Dr Ting in a statement.
'Yet, in East Malaysia, access to reliable information, local expertise, and institutional coordination in CGT remains limited. SSCTR was created to change that,' he added.
The society is guided by a multidisciplinary council comprising pharmacists, clinicians, biotechnologists, educators, and bioprocessing engineers – reflecting the collaborative nature required to advance CGT from research to clinical application.
'Its success relies on coordinated efforts across basic science, clinical practice, manufacturing, regulation, and public engagement.
'That is why our society was founded with an interdisciplinary vision from day one,' he said.
For researchers and healthcare professionals, the SSCTR provides access to the latest developments in CGT, including technological advancements and regulatory frameworks.
It also facilitates national and international collaborations with key organisations such as the International Society for Cell and Gene Therapy (ISCT), the American Society of Gene and Cell Therapy (ASGCT), and the Malaysia Association for Cell and Gene Therapy (MACGT).
The society also promotes interdisciplinary teamwork among molecular scientists, immunologists, stem cell researchers, GMP specialists, clinical trialists, pharmacists, nurses, and regulatory experts.
For the general public, SSCTR aims to raise awareness about both the potential and limitations of CGT.
It also serves as a trusted point of reference for verifying the credibility of CGT-related services and companies.
For government agencies and policymakers, the society offers expert insights to support the development of national and state-level regulations.
It also acts as an intermediary, facilitating communication and advocacy between public authorities, the healthcare sector, and the wider community.
Membership is now open to researchers, clinicians, students, and members of the public who are committed to the ethical and evidence-based advancement of cell and gene therapy.
To learn more or to join the SSCTR, go to the website
